2026-525517-31-00招募中1 期
A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- InflaRx GmbH
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Medical Officer
Scientific
InflaRx GmbH
研究点 (1)
Loading locations...
相似试验
招募中
1 期
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory MyopathySeropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy2025-524100-29-00Ouro Medicines Limited8
已完成
4 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagliflozin tablets 10mg, manufactured by Sun Pharmaceutical Industries Limited, India with Forxiga (Dapagliflozin) film-coated tablets 10 mg, manufactured by AstraZeneca AB Gärtunavägen, SE-151 85 Södertälje Sweden, in healthy adult, human subjects under fasting conditiondiabetes2023-506408-18-00Sun Pharmaceutical Industries Limited48
已完成
4 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.2023-507991-32-00Sun Pharmaceutical Industries Limited32
已完成
4 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaftor film coated tablets 150 mg of Sun Pharmaceutical Industries Ltd, India with Kalydeco (Ivacaftor) 150 mg film-coated tablets, Marketing Authorisation Holder: Vertex Pharmaceuticals (Ireland) Limited Unit 49, Block F2, Northwood Court, Santry, Dublin 9, D09 T665, Ireland, in healthy adult, human subjects under fed condition.Cystic Fibrosis2023-508115-23-00Sun Pharmaceutical Industries Limited52
已完成
1 期
A PHASE 1 STUDY TO ASSESS THE MASS BALANCE, PHARMACOKINETICS, AND METABOLISM OF ORAL [14C]-ZIPALERTINIB IN HEALTHY ADULT MALE SUBJECTSCancer2023-505085-28-00Taiho Oncology Inc.8